BioCryst sinks on HAE updates

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) lost $2.12 (18%) to $9.75 on Thursday after slowing its development timeline for hereditary angioedema therapy avoralstat ( BCX4161) and disclosing discussions with FDA that may delay its NDA submission for the candidate by one year. The company also reported data from a Phase I trial of BCX7353 for HAE.

The company said it will report data in early 2016 from its Phase IIb OPuS-2 trial of avoralstat to prevent HAE; it had expected to do so by YE15. ...